The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.

S. Verazza, S.D. (2017). Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S1), 125-125.

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

M. C. Maggio;
2017-01-01

Abstract

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
Settore MED/38 - Pediatria Generale E Specialistica
23rd Paediatric Rheumatology European Society Congress
Genova
28 September – 01 October
S. Verazza, S.D. (2017). Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S1), 125-125.
File in questo prodotto:
File Dimensione Formato  
PRES2016_MaggioMC_et_al_P216.pdf

accesso aperto

Descrizione: PRES2016_etanercept
Tipologia: Versione Editoriale
Dimensione 49.53 kB
Formato Adobe PDF
49.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/390091
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact